JP6421122B2 - 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 - Google Patents

改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 Download PDF

Info

Publication number
JP6421122B2
JP6421122B2 JP2015536826A JP2015536826A JP6421122B2 JP 6421122 B2 JP6421122 B2 JP 6421122B2 JP 2015536826 A JP2015536826 A JP 2015536826A JP 2015536826 A JP2015536826 A JP 2015536826A JP 6421122 B2 JP6421122 B2 JP 6421122B2
Authority
JP
Japan
Prior art keywords
protein
cell
ompt1
seq
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015536826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531407A (ja
JP2015531407A5 (cg-RX-API-DMAC7.html
Inventor
クリストファー ディー． サノス，
クリストファー ディー． サノス，
クリストファー ジェイ． マレー，
クリストファー ジェイ． マレー，
ジュンハオ ヤン，
ジュンハオ ヤン，
ヘザー スティーブンソン，
ヘザー スティーブンソン，
Original Assignee
ストロ バイオファーマ， インコーポレイテッド
ストロ バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ストロ バイオファーマ， インコーポレイテッド, ストロ バイオファーマ， インコーポレイテッド filed Critical ストロ バイオファーマ， インコーポレイテッド
Publication of JP2015531407A publication Critical patent/JP2015531407A/ja
Publication of JP2015531407A5 publication Critical patent/JP2015531407A5/ja
Application granted granted Critical
Publication of JP6421122B2 publication Critical patent/JP6421122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2015536826A 2012-10-12 2013-10-08 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 Active JP6421122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713245P 2012-10-12 2012-10-12
US61/713,245 2012-10-12
PCT/US2013/063804 WO2014058830A1 (en) 2012-10-12 2013-10-08 Proteolytic inactivation of select proteins in bacterial extracts for improved expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017229231A Division JP2018029621A (ja) 2012-10-12 2017-11-29 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Publications (3)

Publication Number Publication Date
JP2015531407A JP2015531407A (ja) 2015-11-02
JP2015531407A5 JP2015531407A5 (cg-RX-API-DMAC7.html) 2016-11-24
JP6421122B2 true JP6421122B2 (ja) 2018-11-07

Family

ID=49447839

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015536826A Active JP6421122B2 (ja) 2012-10-12 2013-10-08 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
JP2017229231A Withdrawn JP2018029621A (ja) 2012-10-12 2017-11-29 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
JP2020173282A Withdrawn JP2021003134A (ja) 2012-10-12 2020-10-14 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017229231A Withdrawn JP2018029621A (ja) 2012-10-12 2017-11-29 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
JP2020173282A Withdrawn JP2021003134A (ja) 2012-10-12 2020-10-14 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Country Status (14)

Country Link
US (3) US9650621B2 (cg-RX-API-DMAC7.html)
EP (1) EP2906592B1 (cg-RX-API-DMAC7.html)
JP (3) JP6421122B2 (cg-RX-API-DMAC7.html)
KR (1) KR102018863B1 (cg-RX-API-DMAC7.html)
CN (1) CN104837863B (cg-RX-API-DMAC7.html)
AU (1) AU2013329464C1 (cg-RX-API-DMAC7.html)
CA (1) CA2887355C (cg-RX-API-DMAC7.html)
DK (1) DK2906592T3 (cg-RX-API-DMAC7.html)
ES (1) ES2694683T3 (cg-RX-API-DMAC7.html)
HU (1) HUE041721T2 (cg-RX-API-DMAC7.html)
IL (1) IL238095B (cg-RX-API-DMAC7.html)
PL (1) PL2906592T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201502875VA (cg-RX-API-DMAC7.html)
WO (1) WO2014058830A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021003134A (ja) * 2012-10-12 2021-01-14 ストロ バイオファーマ， インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172631A2 (en) * 2013-04-19 2014-10-23 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression
US10316322B2 (en) * 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
CN108779446B (zh) * 2016-01-13 2023-04-21 新英格兰生物实验室公司 T7 rna聚合酶的热稳定变体
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN106801047A (zh) * 2016-12-30 2017-06-06 武汉金开瑞生物工程有限公司 一种通过无细胞蛋白合成系统制备半胱氨酸蛋白酶的方法
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
TW202426655A (zh) 2017-07-11 2024-07-01 美商新索思股份有限公司 非天然核苷酸之導入及其方法
BR112020002272A2 (pt) 2017-08-03 2020-07-28 Synthorx, Inc. conjugados de citocina para o tratamento de doenças autoimunes
EA202090908A1 (ru) 2017-10-12 2020-10-29 Ваксайт, Инк. Вакцина и связанные композиции для лечения пародонтита и способ применения
BR112020017016A2 (pt) 2018-02-26 2020-12-29 Synthorx, Inc. Conjugados da il-15 e usos dos mesmos
JP7340591B2 (ja) * 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CN108949796A (zh) * 2018-07-27 2018-12-07 张家港市华天药业有限公司 一种用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
CN109055291A (zh) * 2018-07-31 2018-12-21 张家港市华天药业有限公司 用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
BR112021005401A2 (pt) 2018-11-08 2021-06-29 Synthorx, Inc. conjugados de interleucina 10 e usos dos mesmos
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
BR112021019826A2 (pt) 2019-04-02 2021-12-07 Vaxcyte Inc Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados
TWI873169B (zh) 2019-08-15 2025-02-21 美商欣爍克斯公司 使用il-2接合物之免疫腫瘤學組合療法
CN114746122A (zh) 2019-09-10 2022-07-12 新索思股份有限公司 Il-2缀合物和治疗自身免疫性疾病的使用方法
IL291786A (en) 2019-11-04 2022-06-01 Synthorx Inc Interleukin 10 conjugates and their use
US12351850B2 (en) * 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
IL299074A (en) 2020-06-25 2023-02-01 Synthorx Inc Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates
EP4211156A1 (en) * 2020-09-14 2023-07-19 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
BR112023006364A2 (pt) 2020-10-09 2023-05-09 Synthorx Inc Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
EP4225375A1 (en) 2020-10-09 2023-08-16 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
WO2022174102A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (zh) 2021-02-12 2022-12-01 美商欣爍克斯公司 Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
CN113322267B (zh) * 2021-03-15 2024-01-05 天津大学 系统在提高非天然氨基酸的插入效率中的应用
TW202313679A (zh) 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
TW202444349A (zh) 2023-03-20 2024-11-16 美商欣爍克斯公司 使用ｉｌ－２綴合物之癌症療法
WO2025015041A1 (en) * 2023-07-12 2025-01-16 University Of Washington Rna-only, positive control target for clinical diagnostic testing
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60040771D1 (de) * 1999-03-04 2008-12-24 Asubio Pharma Co Ltd Verfahren zur kontrolle der spaltung mit ompt protease
WO2002059293A2 (en) 2001-01-25 2002-08-01 Forster Anthony C Process and compositions for peptide, protein and peptidomimetic synthesis
WO2004016778A1 (en) 2002-08-19 2004-02-26 The Board Of Trustees Of The Leland Stanford Junior University Improved methods of in vitro protein synthesis
DE10336705A1 (de) * 2003-08-06 2005-03-10 Rina Netzwerk Rna Technologien Verfahren zur Herstellung eines Lysats zur zellfreien Proteinbiosynthese
ES2398463T3 (es) 2003-09-30 2013-03-19 Daiichi Sankyo Company, Limited Método de escisión de polipéptidos usando un mutante de la proteasa OmpT
WO2006082059A1 (en) * 2005-02-02 2006-08-10 Universität Bayreuth Esterases for monitoring protein biosynthesis in vitro
CN104789536A (zh) 2005-10-12 2015-07-22 斯克利普斯研究院 噬菌体展示多肽的选择性翻译后修饰
WO2007109035A2 (en) * 2006-03-16 2007-09-27 The Scripps Research Institute Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine
EP2379578A4 (en) 2009-01-12 2012-05-02 Sutro Biopharma Inc DOUBLE-LOADING SYSTEM FOR THE SELECTIVE INTRODUCTION OF NON-NITIVE AMINO ACIDS IN PROTEINS DUE TO AN IN VITRO-SYNTHESIS PROCESS
SG11201502875VA (en) * 2012-10-12 2015-06-29 Sutro Biopharma Inc Proteolytic inactivation of select proteins in bacterial extracts for improved expression

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021003134A (ja) * 2012-10-12 2021-01-14 ストロ バイオファーマ， インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Also Published As

Publication number Publication date
PL2906592T3 (pl) 2019-07-31
JP2018029621A (ja) 2018-03-01
ES2694683T3 (es) 2018-12-26
AU2013329464A1 (en) 2015-05-14
US20170283469A1 (en) 2017-10-05
SG11201502875VA (en) 2015-06-29
HUE041721T2 (hu) 2019-05-28
KR102018863B1 (ko) 2019-09-05
US11261219B2 (en) 2022-03-01
DK2906592T3 (en) 2018-12-10
CA2887355A1 (en) 2014-04-17
US20200062807A1 (en) 2020-02-27
KR20150064209A (ko) 2015-06-10
IL238095A0 (en) 2015-05-31
AU2013329464C1 (en) 2018-02-15
CN104837863B (zh) 2018-06-19
CN104837863A (zh) 2015-08-12
JP2021003134A (ja) 2021-01-14
EP2906592B1 (en) 2018-10-03
JP2015531407A (ja) 2015-11-02
AU2013329464B2 (en) 2017-07-27
WO2014058830A1 (en) 2014-04-17
US20150259664A1 (en) 2015-09-17
US10450353B2 (en) 2019-10-22
US9650621B2 (en) 2017-05-16
IL238095B (en) 2019-11-28
CA2887355C (en) 2023-03-07
EP2906592A1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
JP6421122B2 (ja) 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
CN102348807B (zh) 利用体外蛋白合成体系将非天然氨基酸引入蛋白的单装载体系
JP2023116605A (ja) 改変アミノアシルｔＲＮＡ合成酵素およびその用途
US20220243244A1 (en) Compositions and methods for in vivo synthesis of unnatural polypeptides
CN107614689A (zh) 用于将非天然氨基酸并入蛋白质中的平台
Cui et al. Semisynthetic tRNA complement mediates in vitro protein synthesis
US20230076421A1 (en) Methods and compositions for manufacturing polynucleotides
CN112673100B (zh) 包括非标准氨基酸的组合物及其用途
CN107109446A (zh) 顺式‑5‑羟基‑l‑哌可酸的制造方法
WO2023069816A2 (en) Compositions and methods for multiplex decoding of quadruplet codons
WO2015115661A1 (ja) アゾール誘導体骨格を有するペプチドの製造方法
Exner Incorporation of novel noncanonical amino acids in model proteins using rational and evolved variants of Methanosarcina mazei pyrrolysyl-tRNA synthetase
JP5709098B2 (ja) タンパク質の可逆的デュアルラベリング法
JP6804467B2 (ja) 組換え型ヌクレオシド特異的リボヌクレアーゼ及びその生成法と使用法
KR101646728B1 (ko) 디제너러시 리프로그래밍을 통한 비천연 단백질 합성 방법
HK1167003A (en) Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system
LISTING METHODS AND COMPOSITIONS FOR MANUFACTURING POLYNUCLEOTIDES
CN107389945A (zh) 基于体外反应体系筛选黄曲霉sumo化靶蛋白的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181015

R150 Certificate of patent or registration of utility model

Ref document number: 6421122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250